CEST MRI of 3-O-methyl-D-glucose Uptake and Accumulation in Brain Tumors

Overview

Journal Magn Reson Med

Publisher Wiley

Specialty Radiology

Date 2018 Sep 13

PMID 30206994

Citations 23

Authors

Akansha Ashvani Sehgal

Yuguo Li

Bachchu Lal

Nirbhay N Yadav

Xiang Xu

Jiadi Xu

John Laterra

Peter C M van Zijl

Affiliations

Soon will be listed here.

Abstract

Purpose: 3-O-Methyl-D-glucose (3-OMG) is a nonmetabolizable structural analog of glucose that offers potential to be used as a CEST-contrast agent for tumor detection. Here, we explore it for CEST-detection of malignant brain tumors and compare it with D-glucose.

Methods: Glioma xenografts of a U87-MG cell line were implanted in five mice. Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg).

Results: Tumor regions showed higher enhancement as compared to contralateral brain. The CEST contrast enhancement in the tumor region ranged from 2.5-5.0%, while it was 1.5-3.5% in contralateral brain. Previous D-glucose studies of the same tumor model showed an enhancement of 1.5-3.0% and 0.5-1.5% in tumor and contralateral brain, respectively. The signal gradually stabilized to a value that persisted for the length of the scan.

Conclusions: 3-OMG shows a CEST contrast enhancement that is approximately twice as much as that of D-glucose for a similar tumor line. In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors.

Citing Articles

The proton resonance enhancement for CEST imaging and shift exchange (PRECISE) family of RF pulse shapes for CEST MRI.

Mohanta Z, Stabinska J, Gilad A, Barker P, McMahon M Magn Reson Med. 2025; 93(5):1954-1968.

PMID: 39831452 PMC: 11893253. DOI: 10.1002/mrm.30410.

Effect of inhaled oxygen level on dynamic glucose-enhanced MRI in mouse brain.

Huang J, Chen Z, van Zijl P, Law L, Pemmasani Prabakaran R, Park S Magn Reson Med. 2024; 92(1):57-68.

PMID: 38308151 PMC: 11055662. DOI: 10.1002/mrm.30035.

Metabolic brain imaging with glucosamine CEST MRI: in vivo characterization and first insights.

Rivlin M, Perlman O, Navon G Sci Rep. 2023; 13(1):22030.

PMID: 38086821 PMC: 10716494. DOI: 10.1038/s41598-023-48515-5.

Radiofrequency labeling strategies in chemical exchange saturation transfer MRI.

Bie C, van Zijl P, Xu J, Song X, Yadav N NMR Biomed. 2023; 36(6):e4944.

PMID: 37002814 PMC: 10312378. DOI: 10.1002/nbm.4944.

A numerical human brain phantom for dynamic glucose-enhanced (DGE) MRI: On the influence of head motion at 3T.

Lehmann P, Seidemo A, Andersen M, Xu X, Li X, Yadav N Magn Reson Med. 2022; 89(5):1871-1887.

PMID: 36579955 PMC: 9992166. DOI: 10.1002/mrm.29563.

References

Nasrallah F, Pages G, Kuchel P, Golay X, Chuang K . Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab. 2013; 33(8):1270-8. PMC: 3734779. DOI: 10.1038/jcbfm.2013.79. View

Wood K, Hoskin P, Saunders M . Positron emission tomography in oncology: a review. Clin Oncol (R Coll Radiol). 2007; 19(4):237-55. DOI: 10.1016/j.clon.2007.02.001. View

Brooks D, Beaney R, Lammertsma A, Herold S, Turton D, Luthra S . Glucose transport across the blood-brain barrier in normal human subjects and patients with cerebral tumours studied using [11C]3-O-methyl-D-glucose and positron emission tomography. J Cereb Blood Flow Metab. 1986; 6(2):230-9. DOI: 10.1038/jcbfm.1986.36. View

Jenkins A, Menzies I, Nukajam W, Creamer B . The effect of ingested lactulose on absorption of L-rhamnose, D-xylose, and 3-O-methyl-D-glucose in subjects with ileostomies. Scand J Gastroenterol. 1994; 29(9):820-5. DOI: 10.3109/00365529409092517. View

Rivlin M, Tsarfaty I, Navon G . Functional molecular imaging of tumors by chemical exchange saturation transfer MRI of 3-O-Methyl-D-glucose. Magn Reson Med. 2014; 72(5):1375-80. DOI: 10.1002/mrm.25467. View

Herholz K, Wienhard K, Pietrzyk U, Pawlik G, Heiss W . Measurement of blood-brain hexose transport with dynamic PET: comparison of [18F]2-fluoro-2-deoxyglucose and [11C]O-methylglucose. J Cereb Blood Flow Metab. 1989; 9(1):104-10. DOI: 10.1038/jcbfm.1989.14. View

Betz A, GILBOE D . Kinetics of cerebral glucose transport in vivo: inhibition by 3-O-methylglucose. Brain Res. 1974; 65(2):368-72. DOI: 10.1016/0006-8993(74)90052-3. View

Nakanishi H, Cruz N, Adachi K, Sokoloff L, Dienel G . Influence of glucose supply and demand on determination of brain glucose content with labeled methylglucose. J Cereb Blood Flow Metab. 1996; 16(3):439-49. DOI: 10.1097/00004647-199605000-00010. View

Hwang Y, Kim S, Evelhoch J, Ackerman J . Nonglycolytic acidification of murine radiation-induced fibrosarcoma 1 tumor via 3-O-methyl-D-glucose monitored by 1H, 2H, 13C, and 31P nuclear magnetic resonance spectroscopy. Cancer Res. 1992; 52(5):1259-66. View

10.

Sigalet D, Martin G, Meddings J . 3-0 methylglucose uptake as a marker of nutrient absorption and bowel length in pediatric patients. JPEN J Parenter Enteral Nutr. 2004; 28(3):158-62. DOI: 10.1177/0148607104028003158. View

11.

MILLER L, Villeneuve J, Braun L, Oldendorf W . Effect of pharmacological doses of 3-0-methyl-D-glucose and 2-deoxy-D-glucose on rat brain glucose and lactate. Stroke. 1986; 17(5):957-61. DOI: 10.1161/01.str.17.5.957. View

12.

Oldendorf W, Crane P, Lawner P, Braun L . Rapid, transient drop in brain glucose after intravenous phloretin or 3-0-methyl-D-glucose. Stroke. 1983; 14(3):388-93. DOI: 10.1161/01.str.14.3.388. View

13.

Brooks D, Gibbs J, Sharp P, Herold S, Turton D, Luthra S . Regional cerebral glucose transport in insulin-dependent diabetic patients studied using [11C]3-O-methyl-D-glucose and positron emission tomography. J Cereb Blood Flow Metab. 1986; 6(2):240-4. DOI: 10.1038/jcbfm.1986.37. View

14.

Rivlin M, Horev J, Tsarfaty I, Navon G . Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI. Sci Rep. 2013; 3:3045. PMC: 7365327. DOI: 10.1038/srep03045. View

15.

Paech D, Schuenke P, Koehler C, Windschuh J, Mundiyanapurath S, Bickelhaupt S . T1ρ-weighted Dynamic Glucose-enhanced MR Imaging in the Human Brain. Radiology. 2017; 285(3):914-922. DOI: 10.1148/radiol.2017162351. View

16.

Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

17.

Xu X, Chan K, Knutsson L, Artemov D, Xu J, Liu G . Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer. Magn Reson Med. 2015; 74(6):1556-63. PMC: 4715614. DOI: 10.1002/mrm.25995. View

18.

Pardridge W, Oldendorf W . Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta. 1975; 401(1):128-36. DOI: 10.1016/0005-2736(75)90347-8. View

19.

Jin T, Mehrens H, Hendrich K, Kim S . Mapping brain glucose uptake with chemical exchange-sensitive spin-lock magnetic resonance imaging. J Cereb Blood Flow Metab. 2014; 34(8):1402-10. PMC: 4126103. DOI: 10.1038/jcbfm.2014.97. View

20.

van Zijl P, Davis D, Eleff S, Moonen C, Parker R, Strong J . Determination of cerebral glucose transport and metabolic kinetics by dynamic MR spectroscopy. Am J Physiol. 1998; 273(6):E1216-27. DOI: 10.1152/ajpendo.1997.273.6.E1216. View